Pfizer has dedicated an additional half-billion dollars to the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.
This investment follows the original $100m the pharma giant committed in 2017. The facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina research and development sites. In a landscape that is full of up and coming gene therapies, Pfizer is investing so as not to get left behind.
In addition to its gene therapy operations, colleagues at Pfizer’s Sanford facility also manufacture components for the company’s vaccine portfolio, including Prevnar 13 and several vaccines currently in Pfizer’s research pipeline.
This facility would expand the company’s presence in NC, where there are currently more than 3,600 Pfizer colleagues, including 650 in Sanford. The expanded facility is projected to add approximately 300 new jobs.
By expanding its manufacturing footprint in Sanford, Pfizer expects to strengthen its ability to produce and supply both clinical- and commercial-scale quantities of critical, potentially life-changing gene therapy medicines to patients living with rare diseases around the world. Specifically, the new facility would help advance Pfizer’s work in manufacturing highly specialised, potentially one-time gene therapies that use custom-made recombinant adeno-associated virus (rAAV) vectors.
“At Pfizer, our purpose is breakthroughs that change patients’ lives,” said Angela Hwang, Group President, Pfizer Biopharmaceuticals Group. “We’re excited to build this new state-of-the-art facility in Sanford because it will have the potential to help us develop novel methods to deliver transformative treatments to patients.”